Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lawrence Mendelsohn (NPI 1295717189)

Field	Value
Entity Type	Individual
Organization	Lawrence Mendelsohn
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 16, 2005

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider’s billing footprint is concentrated in Medicare with Total Medicare revenue of $3.4M and no Medicaid billing on file, indicating an effectively single-payer (Medicare) practice profile rather than a dual-payer operation. The lack of Medicaid activity should be noted for payer-mix analysis and network strategy.

Revenue concentration is heavy in a small set of infusion drugs: the precomputed top 3 Medicare codes by revenue account for 58.2% of this provider's total Medicare revenue, led by J9271 (26.8K claims, $1.2M revenue, 36.4% of total Medicare revenue), followed by J9299 (20.4K claims, $489.6K revenue, 15.5%) and J0897 (11.3K claims, $203K revenue, 6.4%). This mix (pembrolizumab, nivolumab, denosumab) points to a practice model centered on high-cost oncology/infusion biologics rather than fee-for-service procedural volume alone.

Clinical service-line signals show the provider runs a high-volume outpatient oncology clinic: E/M codes are extreme outliers nationally (99214: 1.5K claims, $131.9K revenue, 4.2% of Medicare revenue — labeled extreme outlier; 99213: 1.8K claims, $102.6K revenue, 3.2% — labeled extreme outlier; 99205: 148 claims, $22.6K revenue, 0.7% — labeled extreme outlier). These elevated E/M volumes, paired with high infusion drug billing, imply substantial ambulatory visit throughput supporting infusion care and new patient evaluations.

Chemotherapy and infusion administration codes further confirm active onsite infusion services: 96413 (1K claims, $87.4K revenue, 2.8% — labeled extreme outlier), 96375 (1.8K claims, $20K revenue, 0.6% — labeled extreme outlier), and 96367 (754 claims, $15.1K revenue, 0.5% — labeled notably above typical national volume) appear prominently. The pattern of high-percentile procedural infusion codes alongside the expensive immunotherapy agents suggests integrated clinic operations that combine drug administration and associated monitoring.

Competitive standing is mixed by code: for the highest-revenue drug J9271 the provider ranks #182 of 1841 (90th percentile; typical, unremarkable volume), and for J9299 ranks #158 of 505 (69th percentile; typical, unremarkable volume), placing the provider in upper national percentiles but described as typical for those specialties. By contrast, some supportive agents and lab/test volumes (for example, J1437 at #46 of 581, 92th percentile; labeled notably above typical national volume) show pockets where this provider bills notably more than peers, indicating selective strengths within certain supportive-care services.

Supportive care and laboratory monitoring are substantial and consistent with oncology follow-up: CBC and phlebotomy codes (85025: 5.6K claims, $45.1K revenue, 1.4% — ranks #297 of 32833, 99th percentile; 36415: 5.5K claims, $44.4K revenue, 1.4% — ranks #307 of 86467, 100th percentile) plus tumor markers and ferritin testing (82378, 86300, 82728) appear at high national percentiles while being described as typical, unremarkable volume. This pattern supports an on-site lab and routine surveillance workflow tied to ongoing cancer therapy.

Biosimilars and growth-factor utilization is evident across the mix: Q5126 (bevacizumab-maly) accounts for $137K revenue (4.3% of Medicare revenue), Q5115 (rituximab-abbs) $127.3K (4.0%), and Q5118 (bevacizumab-bvzr) $61.9K (2.0%), alongside J2506 pegfilgrastim (216 claims, $16K revenue, 0.5% — ranks #501 of 586, 12th percentile). The presence of multiple biosimilar codes and supportive agents indicates active management of biologic therapy regimens and potential sensitivity to biologic-drug procurement and reimbursement dynamics.

Enrollment tenure is long-standing: NPI enumerated since 2005-11-16 (~21 years ago), which indicates a persistent billing history and an established practice pattern. For payer and competitor analysis this tenure, combined with concentrated Medicare revenue and an infusion-heavy code mix, identifies a mature oncology outpatient operation whose revenue is materially driven by high-cost immunotherapies and associated infusion/E/M activity.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

116 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,800	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	20,400	$20	$489.6K
J0897	Injection, denosumab, 1 mg	11,280	$20	$203K
J1437	Injection, ferric derisomaltose, 10 mg	8,600	$20	$146.2K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	2,490	$60	$136.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,520	$90	$131.9K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	3,540	$40	$127.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,800	$60	$102.6K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	15,200	$10	$91.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,010	$90	$87.4K

Showing 1–10 of 116

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 116 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Lawrence Mendelsohn — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

116 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	40	20,700	$40	$896.3K
J9299	10	30	15,660	$20	$432.9K
Q5126	4	10	3,210	$60	$174.1K
J1569	8	10	2,560	$40	$120.3K
J1437	7	20	6,450	$20	$107.8K
J9264	9	10	9,300	$10	$96.2K
Q5115	5	20	2,800	$30	$95.9K
J0897	17	160	2,580	$20	$89.7K
Q5118	3	10	2,110	$20	$64.3K
J2506	7	10	580	$80	$40.4K

Showing 1–10 of 116

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lawrence Mendelsohn, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Jamie Burton	AR	Hematology & Oncology Physician	$2.8M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Appalanaidu Sasapu	AR	Hematology & Oncology Physician	$2.6M	$0
Derek Middleton	AR	Hematology & Oncology Physician	$2.5M	$0

Nearby Providers

Other providers in the same ZIP code as Lawrence Mendelsohn, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Lawrence Mendelsohn — Billing Profile & Reimbursement Data

Sign up for Lawrence Mendelsohn — Billing Profile & Reimbursement Data policy alerts

Lawrence Mendelsohn — Billing Profile & Reimbursement Data

Sign up for Lawrence Mendelsohn — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References